BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27451128)

  • 1. Activation of peroxisome proliferator-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in patients with hepatocellular carcinoma.
    Nojima H; Kuboki S; Shinoda K; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Miyazaki M
    J Hepatobiliary Pancreat Sci; 2016 Sep; 23(9):574-84. PubMed ID: 27451128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma.
    Hsu HT; Sung MT; Lee CC; Kuo YJ; Chi CW; Lee HC; Hsia CY
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
    Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
    Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
    Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
    Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
    Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
    Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
    Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
    Zuo Q; He J; Zhang S; Wang H; Jin G; Jin H; Cheng Z; Tao X; Yu C; Li B; Yang C; Wang S; Lv Y; Zhao F; Yao M; Cong W; Wang C; Qin W
    Hepatology; 2021 Feb; 73(2):644-660. PubMed ID: 32298475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1.
    Pang X; Wei Y; Zhang Y; Zhang M; Lu Y; Shen P
    Cancer Sci; 2013 Jun; 104(6):672-80. PubMed ID: 23461356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
    Schaefer KL; Wada K; Takahashi H; Matsuhashi N; Ohnishi S; Wolfe MM; Turner JR; Nakajima A; Borkan SC; Saubermann LJ
    Cancer Res; 2005 Mar; 65(6):2251-9. PubMed ID: 15781638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
    Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
    Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
    Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
    Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
    Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
    Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
    Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
    Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma.
    Wu CW; Farrell GC; Yu J
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1665-9. PubMed ID: 22742931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
    Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
    Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
    Yu J; Shen B; Chu ES; Teoh N; Cheung KF; Wu CW; Wang S; Lam CN; Feng H; Zhao J; Cheng AS; To KF; Chan HL; Sung JJ
    Hepatology; 2010 Jun; 51(6):2008-19. PubMed ID: 20512989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis.
    Song R; Song H; Liang Y; Yin D; Zhang H; Zheng T; Wang J; Lu Z; Song X; Pei T; Qin Y; Li Y; Xie C; Sun B; Shi H; Li S; Meng X; Yang G; Pan S; Zhu J; Qi S; Jiang H; Zhang Z; Liu L
    Hepatology; 2014 Nov; 60(5):1659-73. PubMed ID: 25042864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression and clinopathological significance of miR-130b in human hepatocellular carcinoma].
    Xu Q; Cai W; Zhang M; Liu Q; Liu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):387-92. PubMed ID: 26927562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
    Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
    Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
    Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.